Page 157 - 南京医科大学自然版

第45卷第5期 陶 媛，季辰菲，吉宁飞. 免疫检查点抑制剂相关肺炎的治疗进展［J］.
2025年5月 南京医科大学学报（自然科学版），2025，45（5）：737-744 ·743 ·

therapy of Cancer（SITC）Toxicity Management Working ［33］ ANDRUSKA N，MAHAPATRA L，HEBBARD C，et al.
Group［J］. J Immunother Cancer，2017，5（1）：95 Severe pneumonitis refractory to steroids following anti ⁃
［22］BRAHMER J R，ABU⁃SBEIH H，ASCIERTO P A，et al. PD ⁃ 1 immunotherapy［J］. BMJ Case Rep，2018，2018：
Society for Immunotherapy of Cancer（SITC） clinical bcr2018225937
practice guideline on immune checkpoint inhibitor⁃relat⁃ ［34］COOKSLEY T，MARSHALL W，GUPTA A. Early inflix⁃
ed adverse events［J］. J Immunother Cancer，2021，9（6）： imab in life⁃threatening immune⁃mediated pneumonitis［J］.
e002435 QJM，2019，112（12）：929-930
［23］HAANEN J G，CARBONNEL F，ROBERT C，et al. Man⁃ ［35］CHEN Z J，HE J. Infliximab in the treatment of tislelizum⁃
agement of toxicities from immunotherapy：ESMO clinical ab⁃induced steroid⁃refractory immune checkpoint inhibi⁃
practice guidelines for diagnosis，treatment and follow⁃ tor⁃related pneumonia ：case report and literature re⁃
up［J］. Ann Oncol，2018，29（Suppl 4）：iv264-iv266 view［J］. Transl Cancer Res，2022，11（9）：3309-3314
［24］ HAANEN J，OBEID M，SPAIN L，et al. Management of ［36］ORTEGA SANCHEZ G，JAHN K，SAVIC S，et al. Treat⁃
toxicities from immunotherapy：ESMO clinical practice ment of mycophenolate⁃resistant immune⁃related organiz⁃
guideline for diagnosis，treatment and follow⁃up［J］. Ann ing pneumonia with infliximab［J］. J Immunother Cancer，
Oncol，2022，33（12）：1217-1238 2018，6（1）：85
［25］中国临床肿瘤学会（CSCO）. 免疫检查点抑制剂相关的 ［37］ LUO J，BEATTIE J A，FUENTES P，et al. Beyond ste⁃
毒性管理指南［M］. 北京：人民卫生出版社，2023：72-82 roids：immunosuppressants in steroid⁃refractory or resis⁃
Chinese Society of Clinical Oncology（CSCO）. Manage⁃ tant immune⁃related adverse events［J］. J Thorac Oncol，
ment of immune checkpoint inhibitor⁃related toxicity［M］. 2021，16（10）：1759-1764
Beijing：People’s Medical Publishing House，2023：72- ［38］ BEATTIE J，RIZVI H，FUENTES P，et al. Success and
82 failure of additional immune modulators in steroid⁃refrac⁃
［26］KARAYAMA M，INUI N，INOUE Y，et al. Six⁃week oral tory/resistant pneumonitis related to immune checkpoint
prednisolone therapy for immune⁃related pneumonitis：a blockade［J］. J Immunother Cancer，2021，9（2）：e001884
single ⁃ arm phase Ⅱ study［J］. J Immunother Cancer， ［39］ DAETWYLER E，WALLRABENSTEIN T，KÖNIG D，et
2023，11（7）：e007056 al. Corticosteroid ⁃ resistant immune ⁃ related adverse
［27］NAIDOO J，COTTRELL T R，LIPSON E J，et al. Chronic events：a systematic review［J］. J Immunother Cancer，
immune checkpoint inhibitor pneumonitis［J］. J Immuno⁃ 2024，12（1）：e007409
ther Cancer，2020，8（1）：e000840 ［40］PEREZ⁃ALVAREZ R，PEREZ⁃DE⁃LIS M，DIAZ⁃LAGAR⁃
［28］ZHOU C Z，YANG Y L，LIN X Q，et al. Proposed clinical ES C，et al. Interstitial lung disease induced or exacerbat⁃
phases for the improvement of personalized treatment of ed by TNF⁃targeted therapies：analysis of 122 cases［J］.
checkpoint inhibitor⁃related pneumonitis［J］. Front Immu⁃ Semin Arthritis Rheum，2011，41（2）：256-264
nol，2022，13：935779 ［41］ SHIOIRI N，KIKUCHI R，MATSUMOTO I，et al. Effec⁃
［29］WANG H P，ZHOU J X，GUO X X，et al. Use of glucocor⁃ tive treatment of steroid⁃resistant immune checkpoint in⁃
ticoids in the management of immunotherapy⁃related ad⁃ hibitor pneumonitis with mycophenolate mofetil［J］. Res⁃
verse effects［J］. Thorac Cancer，2020，11（10）：3047- pirol Case Rep，2024，12（4）：e01356
3052 ［42］MARTINS F，SYKIOTIS G P，MAILLARD M，et al. New
［30］WANG H P，GUO X X，ZHOU J X，et al. Clinical diagno⁃ therapeutic perspectives to manage refractory immune
sis and treatment of immune checkpoint inhibitor⁃associ⁃ checkpoint⁃related toxicities［J］. Lancet Oncol，2019，20
ated pneumonitis［J］. Thorac Cancer，2020，11（1）：191- （1）：e54-e64
197 ［43］HALLOWELL R W，AMARIEI D，DANOFF S K. Intrave⁃
［31］BALAJI A，HSU M，LIN C T，et al. Steroid⁃refractory PD⁃ nous immunoglobulin as potential adjunct therapy for in⁃
（L）1 pneumonitis：incidence，clinical features，treatment， terstitial lung disease［J］. Ann Am Thorac Soc，2016，13
and outcomes［J］. J Immunother Cancer，2021，9（1）： （10）：1682-1688

e001731 ［44］PETRI C R，PATELL R，BATALINI F，et al. Severe pul⁃
［32］LI Y L，JIA X H，ZHANG Y J，et al. Risk factors and im⁃ monary toxicity from immune checkpoint inhibitor treated
munomodulators use in steroid⁃refractory checkpoint in⁃ successfully with intravenous immunoglobulin：case report
hibitor pneumonitis［J］. J Immunother Cancer，2023，11 and review of the literature［J］. Respir Med Case Rep，
（6）：e006982 2019，27：100834